NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

So you are saying one by one a company can not only win new DCVax indications but also simultaneously corner the checkpoint market in that indication and essentially extending patent life for that CI too? Does this suggest to you a plan to stay independent?

There are something like 20 trials running with Keytruda and DCs.

Serching on pembrolizumab Dendritic cell.

Some are ATL type vaccines. Some are not. UCLA even has one in lung cancer that is not related to NWBO even though NWBO is supposedly ready for P2 in lung cancer.

All are early, but the UCLA combo in rGBM is only a P1 also.

The combo patent does nothing to anything other than GBM with an ATL DC vaccine. And it cannot magically be broadened. It originally was very broad, they had to narrow the scope as that was considered unpatentable.

If it actually does work it becomes a race. And now the slow play game has lost the lead.